-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CNTX-6016 in Diabetic Neuropathic Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CNTX-6016 in Diabetic Neuropathic Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CNTX-6016 in Diabetic Neuropathic Pain Drug Details: CNTX-6016 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CNTX-6970 in Osteoarthritis Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CNTX-6970 in Osteoarthritis Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CNTX-6970 in Osteoarthritis PainDrug Details:CNTX-6970 is under development for the treatment of knee...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – capsaicin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry capsaicin Drug Details Capsaicin (Qutenza) is an alkylamide found in capsicum. It is formulated...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CNTX-6016
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry CNTX-6016 Drug Details CNTX-6016 is under development for the treatment of neuropathic pain, painful...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CNTX-6970
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry CNTX-6970 Drug Details CNTX-6970 is under development for the treatment of inflammatory pain. The...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – capsaicin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry capsaicin Drug Details Capsaicin (Qutenza) is an alkylamide found in capsicum. It is formulated...
-
Sector Analysis
Osteoarthritis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2031
Osteoarthritis Market Overview The osteoarthritis market size was valued at $2.5 billion in 2021 and is expected to achieve a CAGR of more than 4% during 2021-2031. OA is a slowly progressive joint disease characterized by degradation of the articular (hyaline) cartilage that coats the bone proximities of synovial joints. Contrary to the previous notion that OA is exclusively a disorder of articular cartilage, studies have demonstrated it is a disease of the whole joint, adversely affecting the subchondral bone,...
-
Product Insights
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
According to the recently published report 'Nociceptin Receptor – Drugs In Development, 2022'; Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) – Nociceptin receptor also known as the nociceptin or orphanin FQ receptor or kappa-type-3 opioid...
-
Product Insights
Osteoarthritis Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Osteoarthritis Pain Pipeline Drugs Market Overview Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain – Drugs In Development, 2022, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape. Osteoarthritis Pain Pipeline Drugs Market is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. If the condition worsens, it leads to rubbing of the bones against each other causing even more pain and loss of movement. Risk factors are age, joint...
-
Product Insights
Somatostatin Receptor Type 4 (SSTR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Somatostatin Receptor Type 4 (SSTR4) pipeline drugs market research report outlays comprehensive information on the Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Hormonal Disorders, Central Nervous System, Metabolic Disorders, and Oncology which include indications of Acromegaly, Diabetic Neuropathic Pain, Low Back Pain, Neuroendocrine Tumors, Osteoarthritis Pain, Pain, and Pituitary ACTH...